Ara
Toplam kayıt 4, listelenen: 1-4
Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer
(Lippincott Williams & Wilkins, 2021)
Background: Efficacy of anti-angiogenic and anti-EGFR agents has been demonstrated metastatic colorectal cancer (mCRC). Real-world evidence is especially important to detect the findings of patients outside of clinical ...
Platelet to lymphocyte ratio is associated with tumor localization and outcomes in metastatic colorectal cancer
(Lippincott Williams & Wilkins, 2021)
The aim of this study was to investigate the predictive and prognostic value of PLR, and the relationship between PLR and tumor localization. A total of 229 patients with de-novo metastatic CRC were retrospectively analyzed. ...
Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102
(Zerbinis Publications, 2019)
Purpose: To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments ...
Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer
(Springer, 2016)
Bevacizumab is a monoclonal antibody which is a vascular endothelial growth factor inhibitor. It obscures vascularization of tumor tissue and damages intratumoral microcirculation. The damaged intratumoral microcirculation ...